Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers

This study has been completed.

Sponsored by:	ISTA Pharmaceuticals
Information provided by:	ISTA Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00586625

Purpose

Safety study for bepotastine besilate ophthalmic solution in normal volunteers

Condition	Intervention
Allergic Conjunctivitis	Drug: bepotastine besilate ophthalmic solution

Study Type:	Observational
Study Design:	Prospective

Further study details as provided by ISTA Pharmaceuticals:

Primary Outcome Measures:

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	850
Study Start Date:	October 2007

Eligibility

Criteria

Inclusion Criteria:

Subjects must be at least 3 years of age, and have ocular health within normal limits

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00586625

Sponsors and Collaborators

ISTA Pharmaceuticals

Investigators

Study Director:

Tim McNamara, PharmD

ISTA Pharmaceuticals, Inc.

More Information

Responsible Party:	ISTA Pharmaceuticals, Inc. ( Tim McNamara, Vice President Clinical Research & Medical Affairs )
Study ID Numbers:	CL-SAF-0405071-P
Study First Received:	December 21, 2007
Last Updated:	December 21, 2007
ClinicalTrials.gov Identifier:	NCT00586625
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Hypersensitivity
Conjunctivitis, Allergic
Eye Diseases

Hypersensitivity, Immediate
Conjunctivitis
Conjunctival Diseases

Additional relevant MeSH terms:

Immune System Diseases

ClinicalTrials.gov processed this record on January 14, 2009